Q3 2023 · 13F-HR
ACUTA CAPITAL PARTNERS, LLCholdings as filed
Filed 2023-11-14 · accession 0001104659-23-117779
$149.2M
Reported value
46
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $12.1M | 8.11% | 3,827,926 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $9.3M | 6.23% | 244,484 | Common | SOLE |
| 00032Q104 | WHWK | AADI BIOSCIENCES INC | $9.0M | 6.00% | 1,849,402 | Common | SOLE |
| 74006W108 | — | PRAXIS PRECISION MEDICINES I | $7.7M | 5.14% | 4,485,000 | Common | SOLE |
| 75525N107 | — | RAYZEBIO INC | $7.6M | 5.13% | 344,571 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $7.6M | 5.08% | 550 | CALL | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $7.4M | 4.97% | 362,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $7.1M | 4.78% | 205,377 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $6.5M | 4.35% | 138,198 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC. | $6.4M | 4.29% | 702,093 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $6.2M | 4.18% | 418,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $6.2M | 4.13% | 121,022 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $5.0M | 3.32% | 129,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $4.3M | 2.89% | 297,035 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $3.6M | 2.44% | 270,319 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $3.5M | 2.37% | 126,500 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $3.4M | 2.31% | 224,339 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC | $3.4M | 2.26% | 122,341 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS INC | $2.8M | 1.87% | 94,000 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $2.8M | 1.87% | 555,260 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $2.6M | 1.72% | 150,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $2.4M | 1.61% | 300,128 | Common | SOLE |
| 45175G108 | — | IKENA ONCOLOGY INC | $2.4M | 1.60% | 551,010 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $2.1M | 1.40% | 323,349 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $1.9M | 1.27% | 153,007 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $1.9M | 1.26% | 15,500 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $1.9M | 1.25% | 230,000 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $1.8M | 1.18% | 1,000 | CALL | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $1.5M | 1.02% | 1,000 | CALL | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $1.4M | 0.95% | 103,600 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $1.3M | 0.88% | 146,500 | Common | SOLE |
| 50107A104 | KRON1USD | KRONOS BIO INC | $934,361 | 0.63% | 718,739 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS | $833,590 | 0.56% | 121,692 | Common | SOLE |
| 10501E201 | BCLIEUR | BRAINSTORM CELL THERAPEUTICS | $825,000 | 0.55% | 2,500 | PUT | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $549,506 | 0.37% | 39,935 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $512,568 | 0.34% | 11,300 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $506,432 | 0.34% | 32,800 | Common | SOLE |
| 52187K200 | CYPH | LEAP THERAPEUTICS INC | $488,749 | 0.33% | 354,166 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $409,200 | 0.27% | 310,000 | Common | SOLE |
| 15117F807 | CLRBUSD | CELLECTAR BIOSCIENCES INC. | $320,232 | 0.21% | 121,300 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $252,100 | 0.17% | 5,000 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $213,864 | 0.14% | 13,300 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMECEUTICALS INC | $156,975 | 0.11% | 19,500 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $126,501 | 0.08% | 99,607 | Common | SOLE |
| 38000Q102 | GLYCEUR | GLYCOMIMETIC INC | $41,250 | 0.03% | 27,500 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $9,083 | 0.01% | 90,832 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.